CCT7 as diabetes biomarker and therapeutic target and diabetes therapeutic drug

By discovering the crotonylation modification level of CCT7 protein and using Ulcerol oligosaccharide to improve the modification level, the side effects and insufficient diagnosis of existing diabetes treatment drugs were solved, and more accurate diagnosis and significant therapeutic effects were achieved, and type 2 diabetes was used to improve the modification level. New biomarkers and therapeutic targets are provided.

CN119019527APending Publication Date: 2024-11-26FUJIAN AGRI & FORESTRY UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411159501.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-22
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Existing diabetes treatment drugs have side effects and lack efficient and low-toxic targets and biomarkers, making it difficult to effectively diagnose and treat type 2 diabetes.

Method used

Compositions for diagnosis and treatment were prepared by discovering the level of crotonylation modification of CCT7 protein as a biomarker and therapeutic target for type 2 diabetes, and using Ulcerol oligosaccharides to enhance the level of crotonylation modification of CCT7 protein.

Benefits of technology

It provides more accurate diagnostic methods and significant therapeutic effects, improving the accuracy and effectiveness of diabetes diagnosis and treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119019527A_ABST
    Figure CN119019527A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to a CCT7 as a biomarker and a therapeutic target of type 2 diabetes and a diabetes therapeutic drug, according to the method, the crotonylation modification level of CCT7 protein is used as the biomarker and the therapeutic target of diabetes, and marine green algae enteromorpha oligosaccharide is used as a therapeutic compound. The enteromorpha oligosaccharide plays a role in relieving diabetes mellitus by regulating and controlling the crotonylation modification level expression of the CCT7 protein. As a natural active component, the enteromorpha oligosaccharide has a good drug development prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine, and specifically relates to CCT7 as a diabetes biomarker and therapeutic target and a diabetes therapeutic drug. Background Art

[0002] Diabetes is a common chronic disease, and its common symptoms include insufficient insulin secretion from the pancreas or low insulin utilization by the body. In 2021, the global prevalence of diabetes among adults aged 20-79 is estimated to be 537 million, mainly type 2 diabetes. By 2045, it is expected to increase by 46% to 783 million. So far, there is no cure for diabetes, but it can be treated with drugs or insulin to maintain blood sugar as close to normal levels as possible and delay or prevent the development of diabetes-related health problems. The main treatment drugs for diabetes are insulin, metformin, pioglitazone, glucagon-like peptide-1 receptor agonists, etc. The above-mentioned hypoglycemic drugs will have side effects on the body of the patients taking them to a certain extent. In the statistics of the use of multiple drug treatments and possible improper drug treatments in middle-aged and elderly diabetic patients, it was found that the rate of patients with multiple drug abuse was 36.9% among patients aged 45-54, 50.3% among patients aged 55-64, and 66.2% among patients over 65 years old. Overdose or incorrect use of medication can lead to life-threatening conditions such as ketoacidosis and hypoglycemia. Although diabetes-related research has made great progress, the discovery of efficient diabetes treatment or prevention targets is still insufficient. Therefore, finding new diabetes treatment targets and developing highly effective and low-toxic diabetes drugs are key issues that need to be addressed.

[0003] In view of the diversity of factors causing diabetes and the diversity of indicators and responses during treatment, the current discovery and application of biomarkers is far from enough, and more and better biomarkers are needed to treat diabetes under various inducing factors. CCT7 (containing TCP1 chaperone protein subunit 7, Gene ID: 10574) is a member of the TCP1 (T complex polypeptide) chaperone family, involved in the folding and unfolding of cytoskeletal proteins, and dysregulated expression is associated with diseases such as tumors, liver cancer, endometrial cancer and myocardial infarction. At present, there are no reports on the correlation between the level of CCT7 crotonylation modification and the occurrence and development of diabetes. Summary of the invention

[0004] In view of the above problems, the present invention provides CCT7 as a biomarker and therapeutic target for type 2 diabetes and a diabetes therapeutic drug.

[0005] The present invention is achieved through the following technical solutions:

[0006] In a first aspect of the present invention, CCT7 is provided as a biomarker and therapeutic target for diabetes, wherein the biomarker and therapeutic target for diabetes is the crotonylation modification level of CCT7 protein, and the amino acid sequence of CCT7 protein is shown in SEQ ID NO. 1. Wherein, the diabetes is type 2 diabetes.

[0007] Based on the above, the second aspect of the present invention provides a composition for improving the crotonylation modification level of CCT7 protein, and its use in preparing a drug for treating diabetes; the composition comprises Enteromorpha oligosaccharide.

[0008] Based on the above, the third aspect of the present invention provides a use of CCT7 protein in preparing a diabetes diagnostic product.

[0009] A fourth aspect of the present invention provides a diabetes treatment drug, wherein the drug takes the crotonylation modification level of the above-mentioned CCT7 protein as a treatment target, and the drug component contains Enteromorpha proliferaoligosaccharide (EPO).

[0010] As a preferred embodiment, further, the method for preparing the Enteromorpha oligosaccharide comprises the following steps:

[0011] 1) mixing Enteromorpha powder with pure water and performing ultrasonic-assisted extraction, centrifuging the extract, vacuum filtering to obtain the supernatant, concentrating the supernatant by rotary evaporation, and then performing alcohol precipitation;

[0012] 2) After alcohol precipitation, centrifuge to take out the precipitate and dry it, dissolve the dried product in pure water, and add protease to the solution for enzymatic hydrolysis;

[0013] 3) After enzymolysis, the enzyme is inactivated and the supernatant is obtained by centrifugation. The supernatant is dialyzed and the liquid in the bag is collected and concentrated and freeze-dried to obtain Enteromorpha polysaccharide;

[0014] 4) Add concentrated sulfuric acid to the aqueous solution of Enteromorpha polysaccharide for acid hydrolysis, cool to room temperature, add NaOH to adjust the solution to neutrality, then perform alcohol precipitation and dialysis, collect the solution outside the bag, concentrate and freeze-dry, and obtain Enteromorpha oligosaccharide.

[0015] As a preferred embodiment, further, in step 1), the particle size of the Enteromorpha powder is 80 mesh, and the Enteromorpha powder and pure water have a solid-liquid ratio of 1:30-1:50;

[0016] Ultrasonic-assisted extraction for 1.5-2.5 hours; the extract was centrifuged at 3500-5500 rpm for 8-15 minutes, and the supernatant was vacuum filtered out, concentrated by rotary evaporation at 55-75°C, and then 3-5 times the volume of 90-100% ethanol was added for precipitation for more than 8 hours.

[0017] As a preferred embodiment, further, in step 2), after alcohol precipitation, centrifuge at 3500-5500 rpm for 8-15 min, take the precipitate and dry it at 55-75° C., then dissolve it in pure water at a solid-liquid ratio of 1:80-120, add protease to the solution so that the enzyme activity is 350-450 U / mL, and perform enzymolysis at 40-55° C. for 1-3 h;

[0018] After enzymatic hydrolysis in step 3), the mixture is incubated in a water bath at 85-100° C. for 15-30 min to inactivate the enzyme, and then centrifuged at 4500-5500 rpm for 8-15 min to obtain the supernatant. The supernatant is dialyzed for 30-60 h using a dialysis bag with a molecular weight of 15 kDa, and the liquid in the bag is collected, concentrated, and freeze-dried to obtain Enteromorpha polysaccharide.

[0019] As a preferred embodiment, further, in step 4), concentrated sulfuric acid is added to the 0.8-1.2% Enteromorpha polysaccharide aqueous solution, and 2-3 mL of concentrated sulfuric acid is added to each liter of Enteromorpha polysaccharide aqueous solution; then, acid hydrolyzed in a water bath at 85-100°C for 1-2 h, cooled to room temperature, 1-2 mol / L NaOH is added to adjust the solution to neutrality, and then 90-100% ethanol solution is added at a volume ratio of 1:1 for alcohol precipitation for 8-15 h, the supernatant is dialyzed in a 3 kDa dialysis bag, and the solution outside the bag is collected, concentrated and freeze-dried to obtain Enteromorpha oligosaccharides.

[0020] The beneficial effects of the present invention are as follows: the CCT7 crotonylation modification level detection method provided by the present invention can be used as a biomarker for rapid diagnosis of type 2 diabetes and can be used as a new target for clinical treatment. Compared with traditional blood sugar and glycosylated hemoglobin detection methods, the detection of this biomarker can provide more accurate and direct reference data, which helps to improve the accuracy of clinical diagnosis. At the same time, the Enteromorpha oligosaccharide drug for treating diabetes provided by the present invention has a simple and easy preparation method and a significant therapeutic effect on diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is the differential expression of CCT7 crotonylation modification levels in rats in the model group (high-sugar and high-fat diet induced type 2 diabetes) and the Enteromorpha oligosaccharide group in Example 1 found under quantitative protein modification omics analysis; wherein, this figure represents the differential upregulation of crotonylation levels in the verification results using protein modification omics (compared with the model group, p<0.05: *, p<0.01: **).

[0022] Figure 2 The effect of the insulin resistance model of HepG2 cells constructed in Example 3 on the viability and glucose consumption of HepG2 cells; wherein, Figure 2-1 and Figure 2-2 To construct an insulin resistance model, changes in HepG2 cell viability and glucose consumption were observed.

[0023] Figure 3 The effect of knocking down the CCT7 gene on the mRNA expression and glucose consumption of HepG2 cells in Example 3; wherein, Figure 3-1 and Figure 3-2 To observe the effect of knocking down the CCT7 gene on the mRNA expression and glucose consumption in the model group. DETAILED DESCRIPTION

[0024] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0025] The present invention provides a biomarker and a therapeutic target for type 2 diabetes. The biomarker and the therapeutic target for diabetes are the crotonylation modification level of CCT7 protein. The amino acid sequence of CCT7 protein is shown in SEQ ID NO.1.

[0026] Based on the above, the present invention also provides a diabetes treatment drug, which uses the crotonylation modification level of the above CCT7 protein as a treatment target, wherein the drug component contains Enteromorpha oligosaccharide (EPO).

[0027] The preparation method of enteromorpha oligosaccharide comprises the following steps:

[0028] Enteromorpha powder (80 mesh) was mixed with pure water at a ratio of 1:30-1:50 (g / mL), and ultrasonic-assisted extraction was performed for 1.5-2.5 hours. The supernatant was vacuum filtered after centrifugation at 3500-5500 rpm for 8-15 minutes, and concentrated by rotary evaporation at 55-75°C, and then 3-5 times the volume of 90-100% ethanol was added for precipitation for more than 8 hours.

[0029] Then, the mixture was centrifuged at 3500-5500 rpm for 8-15 min, the precipitate was dried at 55-75°C, and then dissolved in pure water at a ratio of 1:80-120 (g:mL). Protease was added to the solution to make the enzyme activity 350-450 U / mL. After enzymatic hydrolysis at 40-55°C for 1-3 h, the mixture was then water bathed at 85-100°C for 15-30 min to inactivate the enzyme. The mixture was centrifuged at 4500-5500 rpm for 8-15 min, the supernatant was taken, and the supernatant was dialyzed for 30-60 h using a dialysis bag with a molecular weight of 15 kDa. The liquid in the bag was collected, concentrated and freeze-dried to obtain Enteromorpha polysaccharide.

[0030] Concentrated sulfuric acid is added to a 0.8-1.2% aqueous solution of Enteromorpha polysaccharide (2-3 mL of concentrated sulfuric acid is added per liter of solution), and acid hydrolyzed in a water bath at 85-100° C. for 1-2 hours. After cooling to room temperature, 1-2 mol / L NaOH is added to adjust the solution to neutrality, and then 90-100% ethanol solution is added at a volume ratio of 1:1 for alcohol precipitation for 8-15 hours. The supernatant is dialyzed in a 3 kDa dialysis bag, and the solution outside the bag is collected, concentrated and freeze-dried to obtain Enteromorpha oligosaccharides.

[0031] Example 1: CCT7 crotonylation level as a biomarker for type 2 diabetes

[0032] The specific experimental methods are as follows:

[0033] Analysis of CCT7 crotonylation level by liquid chromatography-mass spectrometry:

[0034] Weigh an appropriate amount of tissue sample into a mortar pre-cooled with liquid nitrogen, add an appropriate amount of liquid nitrogen and grind it until it is fully broken. Transfer the ground tissue to a centrifuge tube and add four times the volume of lysis buffer, and ultrasonically lyse it. Centrifuge at 4℃, 14000rpm for 10min, and transfer the supernatant to a centrifuge tube for protein concentration determination. Add lysis buffer to adjust the protein concentration to a consistent level. Take an equal volume of protein for enzymatic hydrolysis, add 20% trichloroacetic acid, vortex to mix evenly, and precipitate at 4℃ for 2h. Then centrifuge at 4500rpm for 5min, aspirate the supernatant, add pre-cooled acetone to wash the precipitate twice. Vacuum freeze-dry the precipitate. Add 200mMTEAB to the precipitate and ultrasonically break up the precipitate. Add trypsin to the mixture at a ratio of 50:1 protein to trypsin, and enzymatically hydrolyze at 37℃ overnight. Add dithiothreitol (DTT) to make the final concentration of the protein 5mM, and reduce it at 56℃ for 30min. Then add iodoacetamide (IAA) to a final concentration of 11mM, and incubate at room temperature in the dark for 15min. Dissolve the peptide in a buffer solution with a pH of 8.0, containing 0.5% NP-40, 1mM EDTA, 50mM Tris-HCl, and 100mM NaCl. Add the supernatant to the pre-washed crotonylated antibody resin and incubate overnight on a decolorizing shaker at 4°C. After the incubation is completed, add buffer to wash the crotonylated antibody resin 3 times, and then wash with deionized water. Finally, add 0.1% trifluoroacetic acid eluent, elute three times to elute the resin-bound peptide, collect the eluent, and use vacuum freeze drying to dry the eluent. After vacuum freeze drying, it is used for liquid chromatography mass spectrometry analysis. The peptide is dissolved in liquid chromatography mobile phase A and separated using an ultra-high performance liquid system. After separation, it is injected into the Capillary ion source for ionization and then analyzed by timsTOF Pro mass spectrometry. The ion source voltage was set to 1.8 kV, and the peptide precursor ion and its secondary fragments were detected and analyzed using high-resolution TOF. The secondary mass spectrometry scan range was set to 100-1700 m / z. The data acquisition mode used the parallel accumulation serial fragmentation (PASEF) mode.

[0035] The experimental results are as follows:

[0036] The CCT7 crotonylation level in the model group rats (high-sugar and high-fat diet induced type 2 diabetes) and the Enteromorpha oligosaccharide group rats was differentially expressed under quantitative protein modification group analysis. Through 4D Label-free proteomics analysis, combined with bioinformatics analysis, the p value below 0.05 was used as the threshold for significant difference. In the comparison between the model group and the normal group, CCT7 crotonylation showed differential expression, indicating that the crotonylation level of this protein has a potentially important role in type 2 diabetes and is involved in the process of maintaining glucose metabolism function (such as Figure 1 shown).

[0037] Example 2: Preparation of Enteromorpha oligosaccharides

[0038] Weigh 100g Enteromorpha powder (80 mesh) and dissolve it at a solid-liquid ratio of 1:45. Ultrasonic assisted extraction was performed at 60℃, 45kHZ, and 200W power for 1.5h. After centrifugation at 4000rpm for 12min, the precipitate was removed. The supernatant was vacuum filtered and concentrated to 500mL by rotary evaporation. 2L 95% ethanol was added at a ratio of 1:4 to precipitate overnight (more than 8h). Then, it was centrifuged at 5000rpm for 12min to obtain a precipitate, which was placed in a 60℃ oven for drying. The dried precipitate was added with pure water at a ratio of 1:100 and completely dissolved with an electric stirrer. Neutral protease was then added to the solution to make the enzyme activity 400U / mL, and enzymolysis was performed at the optimal temperature for 2h. After enzymolysis, the solution was placed in a 100℃ water bath, inactivated for 25min, and centrifuged at 5000rpm for 12min to remove the precipitate and take the supernatant. The obtained liquid was dialyzed for 48 hours with a dialysis bag with a molecular weight of 15kDa, the solution in the bag was collected and concentrated to 10-20mL, and freeze-dried to obtain Enteromorpha polysaccharide. Weigh 30g of Enteromorpha polysaccharide and dissolve it in pure water to form a 1% polysaccharide solution. Concentrated sulfuric acid was added to adjust the solution concentration to 0.05mol / L. After acid hydrolysis in a 100℃ water bath for 1.5h, it was allowed to stand and cool. After cooling, 1.0mol / L NaOH was added to adjust the solution to neutrality, and then the solution was concentrated. 95% ethanol solution was added at a ratio of 1:1 for alcohol precipitation for more than 8h, and the supernatant was concentrated and freeze-dried to finally obtain Enteromorpha oligosaccharide.

[0039] Example 3: Effect of knocking down the CCT7 gene on glucose content in HepG2 cells

[0040] The specific experimental methods are as follows:

[0041] (1) Construction of HepG2 cell insulin resistance model: Take cells in logarithmic growth phase with good growth status and 5 Cells were inoculated into 96-well plates at a concentration of 100 μg / well. The plated cells were divided into a normal group, a blank control group, and an experimental control group. After the cells adhered to the wall, a medium containing 2% fetal bovine serum (FBS) was added to the normal group. No cells were inoculated in the blank control group, and 2% FBS medium was added. The experimental control group was added with DMEM high-glucose medium containing 4 μM dexamethasone. After incubation for 48 hours, cell viability and glucose consumption were measured.

[0042] (2) Viability assay: Add 10 μL of CCK-8 reagent to each well of the modeled cells, incubate in an incubator for 1 h, and measure the absorbance at 450 nm.

[0043] (3) Glucose determination: After incubating the plated cells for a certain period of time, the culture medium was removed and 100 μL of serum-free culture medium was added. After 24 hours, the culture medium was taken to measure the glucose content, and the OD value of each well was measured at 505 nm using an ELISA reader. The action time and modeling solution concentration with low glucose consumption and no significant effect on cell viability were selected to construct the insulin resistance model.

[0044] (4) Cell transfection: Wash the cells grown to 80-90% with Dulbecco's phosphate buffer 2-3 times, add 1 mL of trypsin, digest for 2 min, remove the supernatant after centrifugation, add culture medium and blow the cells until the cells form a single cell suspension. Count the cells using a hemocytometer and dilute the cells to 1×10 6 cells / ml. According to 2×10 6 Inoculate a 6-well plate at a concentration of 10 cells / well, mix well and culture at 37°C, 5% CO2 for 24 hours. Add 200mL of culture medium without double antibodies and FBS to a 1.5mL eppendorf tube, and then add 3μg of plasmid. Take another 1.5mL eppendorf tube, add 120μL of culture medium without double antibodies and FBS, add 6μL of GP-transfect-Mate transfection reagent, mix well, let it stand at room temperature for 5 minutes, then add the transfection reagent to the tube containing the plasmid, and make it up to 400μL, and let it stand at room temperature for 30 minutes. Aspirate the culture medium in the 6-well plate, and add 1.6mL of 10% FBSDMEM culture medium without double antibodies to each well. Add the transfection mixture dropwise to the 6-well plate, mix well, and incubate in the incubator for 24 hours for RNA extraction.

[0045] (5) Determination of mRNA expression: An insulin resistance cell model was constructed. After 48 hours of plasmid transfection, the culture medium was discarded, 2 mL of PBS was added to wash twice, and Trizol lysis buffer was added to lyse the cells and collected into a centrifuge tube for extraction according to the total RNA column extraction kit. After extracting the total RNA of HepG2 cells, reverse transcription was performed using a reverse transcription kit. The reverse transcription steps are as follows: ① Gene removal reaction: 8uL RNase-Free Water, 1μL gDNA Purge and 1uL total RNA were added respectively, and incubated at 42°C for 5 minutes using a PCR instrument. ② Reverse transcription reaction: Add 10uL cDNA to the first step reaction solution and mix gently. Incubate at 50°C for 15 minutes and at 70°C for 5 minutes in a PCR instrument. After obtaining cDNA, dilute it 5 times with 5×TE buffer and store it at -20°C.

[0046] The experimental results are as follows:

[0047] Glucose consumption in HepG2 cells treated with dexamethasone was significantly reduced compared with that in the control group (p<0.01). Figure 2-1As shown in Figure 2, the phenotype of insulin resistance was shown. For the evaluation of cell activity, CCK-8 reagent was used to measure the intracellular reductase activity, thereby reflecting cell viability. After 48 hours of dexamethasone treatment, the cell viability did not show a statistically significant difference compared with the control group (as shown in Figure 2). Figure 2-2 The results showed that this treatment did not cause toxicity to the cells. The results showed that the insulin resistance model could be effectively established by treating HepG2 cells with 4 μM dexamethasone for 48 h. Figure 3-1 The glucose consumption of HepG2 cells was significantly lower than that of the control group (as shown in Figure 3-2 Diabetic patients often have dysregulated glucose metabolism. Knocking down the CCT7 gene or finding a potential way to restore normal glucose metabolism by increasing crotonylation modification provides new ideas and possible molecular targets for the treatment of diabetes.

[0048] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A CCT7 as a biomarker and therapeutic target for diabetes, characterized in that: The biomarker and therapeutic target for diabetes is the crotonylation modification level of the CCT7 protein, and the amino acid sequence of the CCT7 protein is shown in SEQ ID NO.

1.

2. The biomarker and therapeutic target for diabetes according to claim 1, characterized in that: The diabetes is type 2 diabetes.

3. Use of a composition for increasing the crotonylation modification level of CCT7 protein in the preparation of a drug for treating diabetes.

4. The use according to claim 3, characterized in that: The composition comprises Enteromorpha oligosaccharide.

5. Application of CCT7 protein in the preparation of diabetes diagnostic products.

6. A drug for treating diabetes, characterized in that: The drug takes the crotonylation modification level of the CCT7 protein according to claim 1 as a therapeutic target, and the drug component contains Enteromorpha oligosaccharide.

7. The diabetes therapeutic drug according to claim 2, characterized in that: The preparation method of enteromorpha oligosaccharide comprises the following steps: 1) mixing Enteromorpha powder with pure water and performing ultrasonic-assisted extraction, centrifuging the extract, vacuum filtering to obtain the supernatant, concentrating the supernatant by rotary evaporation, and then performing alcohol precipitation; 2) After alcohol precipitation, centrifuge to take out the precipitate and dry it, dissolve the dried product in pure water, and add protease to the solution for enzymatic hydrolysis; 3) After enzymolysis, the enzyme is inactivated and the supernatant is obtained by centrifugation. The supernatant is dialyzed and the liquid in the bag is collected and concentrated and freeze-dried to obtain Enteromorpha polysaccharide; 4) Add concentrated sulfuric acid to the Enteromorpha polysaccharide aqueous solution for acid hydrolysis, cool to room temperature, add NaOH to adjust the solution to neutrality, then perform alcohol precipitation and dialysis, collect the solution outside the bag, concentrate and freeze-dry, and obtain Enteromorpha oligosaccharide.

8. The diabetes therapeutic drug according to claim 6, characterized in that: In step 1), the particle size of the Enteromorpha powder is 80 mesh, and the Enteromorpha powder and pure water have a solid-liquid ratio of 1:30-1:50; Ultrasonic-assisted extraction for 1.5-2.5 hours; the extract was centrifuged at 3500-5500 rpm for 8-15 minutes, and the supernatant was vacuum filtered out, concentrated by rotary evaporation at 55-75°C, and then 3-5 times the volume of 90-100% ethanol was added for precipitation for more than 8 hours.

9. The diabetes therapeutic drug according to claim 6, characterized in that: In step 2), after alcohol precipitation, centrifuge at 3500-5500 rpm for 8-15 min, take the precipitate and dry it at 55-75° C., then dissolve it in pure water at a solid-liquid ratio of 1:80-120, add protease to the solution so that the enzyme activity is 350-450 U / mL, and perform enzymolysis at 40-55° C. for 1-3 h; After enzymatic hydrolysis in step 3), the mixture is incubated in a water bath at 85-100° C. for 15-30 min to inactivate the enzyme, and then centrifuged at 4500-5500 rpm for 8-15 min to obtain the supernatant. The supernatant is dialyzed for 30-60 h using a dialysis bag with a molecular weight of 15 kDa, and the liquid in the bag is collected, concentrated, and freeze-dried to obtain Enteromorpha polysaccharide.

10. The diabetes therapeutic drug according to claim 6, characterized in that: In step 4), concentrated sulfuric acid is added to the 0.8-1.2% Enteromorpha polysaccharide aqueous solution, and 2-3 mL of concentrated sulfuric acid is added to each liter of Enteromorpha polysaccharide aqueous solution; then acid hydrolyzed in a water bath at 85-100° C. for 1-2 h, cooled to room temperature, 1-2 mol / L NaOH is added to adjust the solution to neutrality, and then 90-100% ethanol solution is added at a volume ratio of 1:1 for alcohol precipitation for 8-15 h, the supernatant is dialyzed in a 3 kDa dialysis bag, the solution outside the bag is collected, concentrated and freeze-dried to obtain Enteromorpha oligosaccharides.